Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. more
Time Frame | MRKR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.63% | -2.12% | -3% |
1-Month Return | 19.5% | -3.42% | -0.73% |
3-Month Return | 29.25% | -11.13% | 2.87% |
6-Month Return | -15.37% | -5.74% | 7.17% |
1-Year Return | -1.3% | 3.97% | 25.31% |
3-Year Return | -63.11% | 1.05% | 28.38% |
5-Year Return | -87.21% | 34.37% | 81.89% |
10-Year Return | -86.81% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 213.19K | 466.79K | 1.24M | 9.00M | 3.31M | [{"date":"2019-12-31","value":2.37,"profit":true},{"date":"2020-12-31","value":5.18,"profit":true},{"date":"2021-12-31","value":13.79,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":36.77,"profit":true}] |
Cost of Revenue | 12.76M | 18.88M | 3.16M | 3.68M | 10.42M | [{"date":"2019-12-31","value":67.61,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":16.75,"profit":true},{"date":"2022-12-31","value":19.49,"profit":true},{"date":"2023-12-31","value":55.17,"profit":true}] |
Gross Profit | (12.55M) | (18.41M) | (1.92M) | 5.32M | (7.11M) | [{"date":"2019-12-31","value":-235.75,"profit":false},{"date":"2020-12-31","value":-345.86,"profit":false},{"date":"2021-12-31","value":-36.08,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-133.46,"profit":false}] |
Gross Margin | (5887.41%) | (3944.85%) | (154.70%) | 59.13% | (214.60%) | [{"date":"2019-12-31","value":-9957.28,"profit":false},{"date":"2020-12-31","value":-6671.86,"profit":false},{"date":"2021-12-31","value":-261.64,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-362.95,"profit":false}] |
Operating Expenses | 22.74M | 29.35M | 40.72M | 38.96M | 17.89M | [{"date":"2019-12-31","value":55.85,"profit":true},{"date":"2020-12-31","value":72.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.68,"profit":true},{"date":"2023-12-31","value":43.94,"profit":true}] |
Operating Income | (22.53M) | (28.89M) | (39.48M) | (29.95M) | (14.58M) | [{"date":"2019-12-31","value":-2252880600,"profit":false},{"date":"2020-12-31","value":-2888581200,"profit":false},{"date":"2021-12-31","value":-3947799500,"profit":false},{"date":"2022-12-31","value":-2994578300,"profit":false},{"date":"2023-12-31","value":-1458137800,"profit":false}] |
Total Non-Operating Income/Expense | 2.18M | 328.48K | (2.40M) | 263.15K | 986.39K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":15.04,"profit":true},{"date":"2021-12-31","value":-109.69,"profit":false},{"date":"2022-12-31","value":12.05,"profit":true},{"date":"2023-12-31","value":45.17,"profit":true}] |
Pre-Tax Income | (21.43M) | (28.71M) | (41.88M) | (29.93M) | (14.04M) | [{"date":"2019-12-31","value":-2142796400,"profit":false},{"date":"2020-12-31","value":-2870607000,"profit":false},{"date":"2021-12-31","value":-4187887100,"profit":false},{"date":"2022-12-31","value":-2993069400,"profit":false},{"date":"2023-12-31","value":-1404222000,"profit":false}] |
Income Taxes | (1.10M) | (179.74K) | (5.70K) | (15.09K) | 3.67K | [{"date":"2019-12-31","value":-29954.88,"profit":false},{"date":"2020-12-31","value":-4890.94,"profit":false},{"date":"2021-12-31","value":-155.1,"profit":false},{"date":"2022-12-31","value":-410.59,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (20.33M) | (28.53M) | (41.87M) | (29.92M) | (14.05M) | [{"date":"2019-12-31","value":-2032712200,"profit":false},{"date":"2020-12-31","value":-2852632800,"profit":false},{"date":"2021-12-31","value":-4187317100,"profit":false},{"date":"2022-12-31","value":-2991560500,"profit":false},{"date":"2023-12-31","value":-1404589500,"profit":false}] |
Income From Continuous Operations | (21.43M) | (28.71M) | (41.88M) | (29.93M) | (24.50M) | [{"date":"2019-12-31","value":-2142796400,"profit":false},{"date":"2020-12-31","value":-2870607000,"profit":false},{"date":"2021-12-31","value":-4187887100,"profit":false},{"date":"2022-12-31","value":-2993069400,"profit":false},{"date":"2023-12-31","value":-2450390000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (20.33M) | (28.53M) | (41.87M) | (29.92M) | (14.05M) | [{"date":"2019-12-31","value":-2032712200,"profit":false},{"date":"2020-12-31","value":-2852632800,"profit":false},{"date":"2021-12-31","value":-4187317100,"profit":false},{"date":"2022-12-31","value":-2991560500,"profit":false},{"date":"2023-12-31","value":-1404589500,"profit":false}] |
EPS (Diluted) | (4.70) | (6.20) | (5.30) | (3.58) | (1.10) | [{"date":"2019-12-31","value":-470,"profit":false},{"date":"2020-12-31","value":-620,"profit":false},{"date":"2021-12-31","value":-530,"profit":false},{"date":"2022-12-31","value":-358,"profit":false},{"date":"2023-12-31","value":-110.16,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MRKR | |
---|---|
Cash Ratio | 2.60 |
Current Ratio | 3.15 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MRKR | |
---|---|
ROA (LTM) | -40.87% |
ROE (LTM) | -71.74% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MRKR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.32 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.68 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MRKR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 8.93 |
P/B | 4.86 |
Price/FCF | 28 |
EV/R | 3.41 |
EV/Ebitda | NM |
Marker Therapeutics Inc (MRKR) share price today is $3.8
Yes, Indians can buy shares of Marker Therapeutics Inc (MRKR) on Vested. To buy Marker Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MRKR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Marker Therapeutics Inc (MRKR) via the Vested app. You can start investing in Marker Therapeutics Inc (MRKR) with a minimum investment of $1.
You can invest in shares of Marker Therapeutics Inc (MRKR) via Vested in three simple steps:
The 52-week high price of Marker Therapeutics Inc (MRKR) is $6.16. The 52-week low price of Marker Therapeutics Inc (MRKR) is $2.44.
The price-to-earnings (P/E) ratio of Marker Therapeutics Inc (MRKR) is
The price-to-book (P/B) ratio of Marker Therapeutics Inc (MRKR) is 4.86
The dividend yield of Marker Therapeutics Inc (MRKR) is 0.00%
The market capitalization of Marker Therapeutics Inc (MRKR) is $33.28M
The stock symbol (or ticker) of Marker Therapeutics Inc is MRKR